雷帕鸣（西罗莫司片）纳入医保了吗？

Sirolimus is a new type of macrolide immunosuppressant. It is a white solid crystal with a melting point of 183-185°C. It is lipophilic and soluble in methanol, ethanol, acetone, chloroform and other organic solvents. It is very slightly soluble in water and almost insoluble in ether. It was initially used as a low-toxic antifungal drug. In 1977, it was found to have immunosuppressive effects. In 1989, RAPA began to be tried out as a new drug to treat rejection of organ transplants. Judging from the effects of animal experiments and clinical applications, it is a new immunosuppressant with good efficacy, low toxicity, and no nephrotoxicity. It is now often used as a drug to maintain the immunity of transplanted organs (especially kidney transplants) to slow down immune rejection after organ transplantation. However, scientists have recently discovered another use for it: it can be used to treat Alzheimer's disease (senile dementia).

Sirolimus is a lipophilic nitrogen-containing 36$ macrolide antibiotic naturally produced from Streptomyees hygroscopicus, with a molecular formula of It is C51H79NO13, with a molecular weight of 914.17. Sirolimus (sirolimus), as a macrolide compound, is a less toxic and potentially powerful new immunosuppressant discovered so far. It can extend the survival period after transplantation, reduce the occurrence of acute rejection, and provides a new treatment alternative for transplant recipients.

In 2003, sirolimus (sirolimus) was approved for marketing in China. Is sirolimus included in medical insurance?

It is understood that sirolimus (sirolimus) has been included in the national medical insurance directory, but patients are advised to consult the local medical insurance bureau for specific reimbursement ratios and conditions.